What development phase is Procoxacin in?

Procoxacin is FDA-approved (marketed).

What is the generic name of Procoxacin?

SALINOMYCIN is the generic (nonproprietary) name of Procoxacin.

Last reviewed 2026-04-20 · How we verify

Procoxacin (SALINOMYCIN)

FDA-approved active Small molecule Quality 0/100

Salinomycin (Procoxacin) is a marketed antibiotic that inhibits protein synthesis in bacteria, though its primary indication and revenue figures are not specified. A key strength is its protected market position, with the key composition patent expiring in 2028. The primary risk is the lack of detailed clinical trial results and competitor information, which may impact its market competitiveness.

At a glance

Generic name	SALINOMYCIN
Modality	Small molecule
Therapeutic area	Infectious Disease
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Procoxacin CI brief — competitive landscape report
Procoxacin updates RSS · CI watch RSS